HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A4063 Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa
A4064 Vanucizumab (Anti-Angiopoietin 2 & VEGF) Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa
A4066 Vudalimab (Anti-CTLA4 & PD-1) Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa
A4067 Zenocutuzumab (Anti-HER2 & HER3) Zenocutuzumab is a humanized bispecific IgG1 antibody targeting HER2 and HER3 to enhance antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth. It is being developed for the treatment of cancers overexpressing HER2 and HER3, leveraging dual targeting for enhanced antitumor activity. M. W 145.88 kDa
A4068 Lomvastomig (Anti-PD-1 & TIM-3) Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa
A4070 M701 (Anti-CD3 & EpCAM) M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa
A4071 Regn5678 (Anti-CD28 & PSMA) REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa
A4072 Flotetuzumab (Anti-CD3 & CD123) Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa
A4005 Erfonrilimab (Anti-CTLA4 & PD-L1) Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
E5818 Fedratinib hydrochloride hydrate Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate) is a small-molecule, ATP-competitive inhibitor of JAK2 with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. It induces cancer cell apoptosis and has potential for efficacious treatment of JAK2V617F-associated myeloproliferative disease.
S6992 Calcium chloride Calcium chloride (CaCl2) is an ionic compound used for calcium supplementation in conditions like hypocalcemia and hyperkalemia and as an antidote for magnesium toxicity. It also functions as a co-adjuvant in hemostatic formulations and effectively treats refractory hypotension and complete heart block. It enhances the activity of MoPtc1 and MoPtc2, type 2C protein phosphatases involved in the ionic stress response and MAPK signalling regulation in Magnaporthe oryzae. It can also be used as a desiccant and dehydrating agent.
E6003 Gabapentin enacarbil Gabapentin enacarbil (XP13512) is a prodrug of gabapentin, designed to enhance gabapentin absorption and bioavailability and treats restless legs syndrome. It also acts as an anticonvulsant and analgesic within the gabapentinoid class.
P1247 Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
E1230 Vaborbactam Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.
E8146 Citric acid trisodium Citric acid trisodium is a natural preservative and food tartness enhancer. Citric acid trisodium induces apoptosis and cell cycle arrest at G2/M phase and S phase. Citric acid trisodium cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid trisodium causes renal toxicity in mice.
E8181 Glucagon (1-29), bovine, human Glucagon (1-29), bovine, human (Glucagon) is secreted by pancreatic α-cells, and acts as an inhibitor of CYP7A1 by strongly stimulating HNF4α phosphorylation, which reduces HNF4α's DNA binding and transactivation of the CYP7A1 gene. It activates gluconeogenesis to maintain glucose homeostasis and energy metabolism, making it useful in research on type 2 diabetes mellitus (T2DM).
E6027 Ibuprofen sodium Ibuprofen ((±)-Ibuprofen sodium) sodium is an orally active, selective inhibitor of COX-1 with an IC50 value of 13 μM. Ibuprofen formulated as a sodium salt is absorbed twice as quickly as from its standard ibuprofen acid.
E6025 Palbociclib 2HCL Palbociclib 2HCL (PD-0332991 dihydrochloride), the dihydrochloride salt of Palbociclib, is a highly specific inhibitor of Cdk4 and Cdk6, with IC50 values of 11 nM and 16 nM, respectively. It is a potent antiproliferative agent against retinoblastoma (Rb)-positive tumor cells in vitro, inducing a selective G1 cell cycle arrest and reducing phosphorylation at Ser780 and Ser795 on the Rb protein.
E6002 Ledipasvir D-tartrate Ledipasvir D-tartrate (GS-5885 D-tartrate), the D-tartrate salt form of ledipasvir, is an inhibitor of the HCV NS5A, which is essential for the replication of the virus. It exhibits EC50 of 31 pM against GT1a and 4 pM against GT1b replicons.
E6029 Lenalidomide hemihydrate Lenalidomide hemihydrate (CC-5013 hemihydrate) is a potent inhibitor of TNF-alpha with a IC50 of 13 nM. It induces tyrosine phosphorylation of CD28 on T cells, which subsequently activates NF-κB. It acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN), leading to the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase complex.